Blockade of tolerance to morphine analgesia by cocaine.
Tolerance to morphine analgesia was induced in male Sprague-Dawley rats by s.c. implantation of a morphine base pellet (75 mg) on the first and second day and determining the magnitude of tolerance 72 h after the first implant by s.c. injection of a test dose of morphine (5 mg/kg). Implantation of a cocaine hydrochloride pellet (25 mg), concurrently with morphine pellets or of a cocaine hydrochloride (50 mg) pellet after the development of tolerance, blocked both the development and expression of morphine analgesic tolerance. In morphine-pelleted animals pretreatment for 3 days with desipramine or zimelidine or phenoxybenzamine but not haloperidol produced no significant morphine tolerance. Pretreatment with a combination of desipramine and zimelidine, however, was as effective as cocaine in blocking morphine tolerance. Alpha-Methyl-p-tyrosine methyl ester counteracted the effect of cocaine in blocking morphine tolerance and potentiated the tolerance development. Blockade of morphine tolerance by cocaine was reinforced and facilitated by pretreatment with fenfluramine or p-chlorophenylalanine ethyl ester and to a lesser extent by clonidine and haloperidol. Acute administration of fenfluramine or zimelidine or a combination of desipramine and zimelidine or alpha-methyl-p-tyrosine methyl ester or p-chlorophenylalanine ethyl ester did not significantly affect morphine analgesia. The study suggests an important role of the concomitant depletion of both central noradrenaline and serotonin in the blockade of morphine tolerance by cocaine and stresses the importance of the counter-balancing functional relationship between these two neurotransmitters in the central nervous system.
New York State Division of Substance Abuse Services, Testing and Research Laboratory, Brooklyn, NY 11217 U.S.A. State university of New York, Department of Psychiatry, Health Science Center, Brooklyn, NY 11203 U.S.A.
Anand L
AL
Misra
Ronald B
RB
Pontani
Narasimhan L
NL
Vadlamani
D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D003042:Cocaine / Q000378:metabolism / Q000627:therapeutic use*; D004343:Drug Implants; D004361:Drug Tolerance; D008297:Male; D009020:Morphine / Q000378:metabolism / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains
D000700:Analgesics; D004343:Drug Implants; D009020:Morphine; D003042:Cocaine